Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,777
  • Shares Outstanding, K 45,090
  • Annual Sales, $ 23,070 K
  • Annual Income, $ -53,690 K
  • 60-Month Beta 2.26
  • Price/Sales 1.68
  • Price/Cash Flow N/A
  • Price/Book 0.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.58
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.27
  • Low Estimate -0.48
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +34.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.70 +26.36%
on 05/31/19
0.93 -5.43%
on 06/14/19
+0.10 (+12.58%)
since 05/14/19
3-Month
0.67 +31.27%
on 05/02/19
1.03 -14.61%
on 03/25/19
+0.03 (+3.47%)
since 03/14/19
52-Week
0.67 +31.27%
on 05/02/19
5.97 -85.27%
on 06/22/18
-4.16 (-82.55%)
since 06/14/18

Most Recent Stories

More News
Aptevo Therapeutics Reports First Quarter 2019 Financial Results

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY(R) Net Revenue

APVO : 0.88 (+2.27%)
5 Stocks to Gain From Dollar's Recent Strength

The U.S. dollar hits an almost 2-year record high as global central banks turn dovish and German business moral deteriorates.

GTIM : 2.01 (+8.65%)
BFIN : 13.91 (-1.21%)
APVO : 0.88 (+2.27%)
HIIQ : 27.87 (+0.32%)
ADES : 12.86 (-0.77%)
Research Report Identifies Fastenal, Ideal Power, Fuel Tech, CTI BioPharma, Aptevo Therapeutics, and Caseys General Stores with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fastenal Company (NASDAQ:FAST),...

IPWR : 0.32 (unch)
CTIC : 0.92 (+5.44%)
FTEK : 1.38 (-7.38%)
APVO : 0.88 (+2.27%)
CASY : 151.98 (-0.20%)
FAST : 31.65 (-3.30%)
Aptevo Therapeutics Reports IXINITY(R) and Pipeline Progress

Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019

APVO : 0.88 (+2.27%)
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting

APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation...

APVO : 0.88 (+2.27%)
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR(TM)...

APVO : 0.88 (+2.27%)
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation

APVO : 0.88 (+2.27%)
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update

Achieves Record Annual IXINITY Net Revenue of $23.1 Million Representing 111% Increase Over 2017

APVO : 0.88 (+2.27%)
Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APVO : 0.88 (+2.27%)
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering...

APVO : 0.88 (+2.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators are in flux.

See More Share

Trade APVO with:

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

2nd Resistance Point 0.97
1st Resistance Point 0.92
Last Price 0.88
1st Support Level 0.84
2nd Support Level 0.81

See More

52-Week High 5.97
Fibonacci 61.8% 3.95
Fibonacci 50% 3.32
Fibonacci 38.2% 2.69
Last Price 0.88
52-Week Low 0.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar